Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK
and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with
Atezolizumab in patients with locally advanced/metastatic tumors.